XTL Biopharma Announces Meeting Results
Ticker: XTLB · Form: 6-K · Filed: Jul 22, 2024 · CIK: 1023549
| Field | Detail |
|---|---|
| Company | Xtl Biopharmaceuticals Ltd (XTLB) |
| Form Type | 6-K |
| Filed Date | Jul 22, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $430,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-meeting, corporate-governance, results-announcement
TL;DR
XTL Biopharma held its shareholder meeting today, July 22, 2024, and announced the results.
AI Summary
XTL Biopharmaceuticals Ltd. announced the results of its Annual and Extraordinary General Meeting of Shareholders held on July 22, 2024. The meeting was originally announced on June 12, 2024, and took place at the offices of the Company's attorneys in Bnei Brak, Israel.
Why It Matters
Shareholder meetings are crucial for corporate governance, allowing investors to vote on important company matters and influence strategic direction.
Risk Assessment
Risk Level: low — This filing is a routine announcement of meeting results and does not contain new financial or operational information that would typically increase risk.
Key Players & Entities
- XTL Biopharmaceuticals Ltd. (company) — Registrant
- July 22, 2024 (date) — Date of Meeting and Announcement
- June 12, 2024 (date) — Date of Original Meeting Announcement
- Doron Tikotzky Kantor Gutman & Amit Gross (company) — Company's Attorneys
FAQ
What was the purpose of the Annual and Extraordinary General Meeting of Shareholders?
The filing states the meeting was held to announce the results of the meeting, implying shareholder votes on various company matters took place.
When was the Annual and Extraordinary General Meeting of Shareholders held?
The meeting was held on July 22, 2024.
Where was the meeting held?
The meeting was held at the offices of the Company's attorneys, Doron Tikotzky Kantor Gutman & Amit Gross, located at 7 Metsada St., B.S.R Tower 4, 33 Floor, Bnei Brak, Israel.
What is XTL Biopharmaceuticals Ltd.'s primary business?
XTL Biopharmaceuticals Ltd. is in the Pharmaceutical Preparations industry, SIC code 2834.
Is XTL Biopharmaceuticals Ltd. required to file annual reports on Form 20-F or 40-F?
Yes, XTL Biopharmaceuticals Ltd. indicated it files annual reports under Form 20-F.
Filing Stats: 685 words · 3 min read · ~2 pages · Grade level 10 · Accepted 2024-07-22 16:00:02
Key Financial Figures
- $430,000 — of the Company and (b) the payment of US$430,000 in cash to the shareholders of Social P
Filing Documents
- ea0209792-6k_xtlbio.htm (6-K) — 17KB
- 0001013762-24-000446.txt ( ) — 18KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. XTL BIOPHARMACEUTICALS LTD. Date: July 22, 2024 By: /s/ Shlomo Shalev Shlomo Shalev Chief Executive Officer 2